Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

July 1, 2025

Conditions

Keloids

Interventions

DRUG

Bevacizumab

anti-VEGF

DRUG

Triamcinolone Acetonide

corticosteroid

Trial Locations (1)

Kasr El Ainy University Hospital, faculty of medicine, Cairo university, Cairo

All Listed Sponsors

lead

Kasr El Aini Hospital

OTHER

NCT07014280 - Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids. | Biotech Hunter | Biotech Hunter